Kuo and Liang [78] developed cationic solid lipid nanoparticles (CASLNs) with the inclusion of a monoclonal antibody (mAb) directed against the epidermal growth factor receptor (EGFR) carrying carmustatine (BCNU), a lipophilic chemotherapy drug used for brain tumors, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. This evidence concerns the gene EGFR and non-Hodgkin lymphoma.